Search Results - "Skrahina, A"

Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains by Battaglia, S, Spitaleri, A, Cabibbe, A M, Meehan, C J, Utpatel, C, Ismail, N, Tahseen, S, Skrahina, A, Alikhanova, N, Mostofa Kamal, S M, Barbova, A, Niemann, S, Groenheit, R, Dean, A S, Zignol, M, Rigouts, L, Cirillo, D M

“…The role of mutations in genes associated with phenotypic resistance to bedaquiline (BDQ) and delamanid (DLM) in complex (MTBc) strains is poorly…”
Get full text

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis by Migliori, G. B, Eker, B, Richardson, M. D, Sotgiu, G, Zellweger, J-P, Skrahina, A, Ortmann, J, Girardi, E, Hoffmann, H, Besozzi, G, Bevilacqua, N, Kirsten, D, Centis, R, Lange, C, TBNET Study Group

“…Linezolid is used to treat patients with multidrug-resistant (MDR)/extensively drug-resistant (XDR)-tuberculosis (TB) cases, although clinical data on its…”
Get full text

Clinical standards for the diagnosis, treatment and prevention of TB infection by Migliori, G. B., Wu, S. J., Matteelli, A., Zenner, D., Goletti, D., Ahmedov, S., Al-Abri, S., Allen, D. M., Balcells, M. E., Garcia-Basteiro, A. L., Cambau, E., Chaisson, R. E., Chee, C. B. E., Dalcolmo, M. P., Denholm, J. T., Erkens, C., Esposito, S., Farnia, P., Friedland, J. S., Graham, S., Hamada, Y., Harries, A. D., Kay, A. W., Kritski, A., Manga, S., Marais, B. J., Menzies, D., Ng, D., Petrone, L., Rendon, A., Silva, D. R., Schaaf, H. S., Skrahina, A., Sotgiu, G., Thwaites, G., Tiberi, S., Tukvadze, N., Zellweger, J.-P., D´Ambrosio, L., Centis, R., Ong, C. W. M.

“…BACKGROUND: Tuberculosis (TB) preventive therapy (TPT) decreases the risk of developing TB disease and its associated morbidity and mortality. The aim of these…”
Get full text

Whole-genome sequencing differentiates relapse from re-infection in TB by Nikolenka, A., Mansjö, M., Skrahina, A., Hurevich, H., Grankov, V., Nikisins, S., Dara, M., Ehsani, S., Groenheit, R.

“…BACKGROUND: Distinguishing TB relapse from re-infection is important from a clinical perspective to document transmission patterns. We investigated isolates…”
Get full text

Clinical standards for the dosing and management of TB drugs by Alffenaar, J. W. C., Stocker, S. L., Forsman, L. Davies, Garcia-Prats, A., Heysell, S. K., Aarnoutse, R. E., Akkerman, O. W., Aleksa, A., van Altena, R., de Oñata, W. Arrazola, Bhavani, P. K., van't Boveneind-Vrubleuskaya, N., Carvalho, A. C. C., Centis, R., Chakaya, J. M., Cirillo, D. M., Cho, J. G., D´Ambrosio, L., Dalcolmo, M. P., Denti, P., Dheda, K., Fox, G. J., Hesseling, A. C., Kim, H. Y., Köser, C. U., Marais, B. J., Margineanu, I., Märtson, A. G., Torrico, M. Munoz, Nataprawira, H. M., Ong, C. W. M., Otto-Knapp, R., Peloquin, C. A., Silva, D. R., Ruslami, R., Santoso, P., Savic, R. M., Singla, R., Svensson, E. M., Skrahina, A., van Soolingen, D., Srivastava, S., Tadolini, M., Tiberi, S., Thomas, T. A., Udwadia, Z. F., Vu, D. H., Zhang, W., Mpagama, S. G., Schön, T., Migliori, G. B.

“…BACKGROUND: Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim…”
Get full text

Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries by Guglielmetti, L., Hewison, C., Avaliani, Z., Hughes, J., Kiria, N., Lomtadze, N., Ndjeka, N., Setkina, S., Shabangu, A., Sikhondze, W., Skrahina, A., Veziris, N., Furin, J.

“…BACKGROUND: For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and…”
Get full text

Management of childhood MDR-TB in Europe and Central Asia: report of a Regional WHO meeting by Gröschel, M. I., van den Boom, M., Dixit, A., Skrahina, A., Dodd, P. J., Migliori, G. B., Seddon, J. A., Farhat, M. R., WHO Regional Meeting Participants

“…BACKGROUND: As the WHO European Region has the highest proportion of multidrug-resistant TB (MDR-TB) among total incident TB cases, many children and…”
Get full text

Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes by Campbell, J. R., Chan, E. D., Anderson, L. F., Bonnet, M., Brode, S. K., Cegielski, J. P., Guglielmetti, L., Singla, R., Fox, G. J., Skrahina, A., Rodrigues, D., Kuksa, L., Viiklepp, P., Menzies, D.

Get full text

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications by Rich, M. L., Khan, U., Zeng, C., LaHood, A., Franke, M. F., Atwood, S., Bastard, M., Burhan, E., Danielyan, N., Dzhazibekova, P. M., Gadissa, D., Ghafoor, A., Hewison, C., Islam, M. S., Kazmi, E., Khan, P. Y., Lecca, L., Maama, L. B., Melikyan, N., Naing, Y. Y., Philippe, K., Saki, N. A., Seung, K. J., Skrahina, A., Tefera, G. B., Varaine, F., Vilbrun, S. C., Võ, L., Mitnick, C. D., Huerga, H., on behalf of the endTB Observational Study Team

“…BACKGROUND: Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB)…”
Get full text

Access to experimental medicines for TB: ethical and human rights considerations by Dagron, S., Chakhaia, T., González-Angulo, L., Hermanns, S., Skrahina, A., Wallace, A. E. M.

“…The revised edition of the WHO's Ethics Guidance for the Implementation of the TB Strategy has added a new chapter on compassionate use (CU) and expanded…”
Get full text

Clinical standards for the management of adverse effects during treatment for TB by Singh, K. P., Carvalho, A. C. C., Centis, R., D´Ambrosio, L., Migliori, G. B., Mpagama, S. G., Nguyen, B. C., Aarnoutse, R. E., Aleksa, A., van Altena, R., Bhavani, P. K., Bolhuis, M. S., Borisov, S., van´t Boveneind-Vrubleuskaya, N., Bruchfeld, J., Caminero, J. A., Carvalho, I., Cho, J. G., Davies Forsman, L., Dedicoat, M., Dheda, K., Dooley, K., Furin, J., García-García, J. M., Garcia-Prats, A., Hesseling, A. C., Heysell, S. K., Hu, Y., Kim, H. Y., Manga, S., Marais, B. J., Margineanu, I., Märtson, A-G., Munoz Torrico, M., Nataprawira, H. M., Nunes, E., Ong, C. W. M., Otto-Knapp, R., Palmero, D. J., Peloquin, C. A., Rendon, A., Rossato Silva, D., Ruslami, R., Saktiawati, A. M. I., Santoso, P., Schaaf, H. S., Seaworth, B., Simonsson, U. S. H., Singla, R., Skrahina, A., Solovic, I., Srivastava, S., Stocker, S. L., Sturkenboom, M. G. G., Svensson, E. M., Tadolini, M., Thomas, T. A., Tiberi, S., Trubiano, J., Udwadia, Z. F., Verhage, A. R., Vu, D. H., Akkerman, O. W., Alffenaar, J. W. C., Denholm, J. T.

“…BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage…”
Get full text

Clinical standards for drug-susceptible TB in children and adolescents by Chiang, S. S., Graham, S. M., Schaaf, H. S., Marais, B. J., Sant'Anna, C. C., Sharma, S., Starke, J. R., Triasih, R., Achar, J., Amanullah, F., Armitage, L. Y., Aurilio, R. B., Buck, W. C., Centis, R., Chabala, C., Cruz, A. T., Demers, A.-M., du Preez, K., Enimil, A., Furin, J., Garcia-Prats, A. J., Gonzalez, N. E., Hoddinott, G., Isaakidis, P., Jaganath, D., Kabra, S. K., Kampmann, B., Kay, A., Kitai, I., Lopez-Varela, E., Maleche-Obimbo, E., Malaspina, F. Mestanza, Velásquez, J. Niederbacher, Nuttall, J. J. C., Oliwa, J. N., Andrade, I. Orozco, Perez-Velez, C. M., Rabie, H., Seddon, J. A., Sekadde, M. P., Shen, A., Skrahina, A., Soriano-Arandes, A., Steenhoff, A. P., Tebruegge, M., Tovar, M. A., Tsogt, B., van der Zalm, M. M., Welch, H., Migliori, G. B.

“…BACKGROUND: These clinical standards aim to provide guidance for diagnosis, treatment, and management of drug-susceptible TB in children and…”
Get full text

Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB by Cox, V., McKenna, L., Acquah, R., Reuter, A., Wasserman, S., Vambe, D., Ustero, P., Udwadia, Z., Triviño-Duran, L., Tommasi, M., Skrahina, A., Seddon, J. A., Rodolfo, R., Rich, M., Padanilam, X., Oyewusi, L., Ohler, L., Lungu, P., Loveday, M., Khan, U., Khan, P., Hughes, J., Hewison, C., Guglielmetti, L., Furin, J.

“…Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB)…”
Get full text

Standards for clinical trials for treating TB by du Cros, P., Greig, J., Alffenaar, J.-W. C., Cross, G. B., Cousins, C., Berry, C., Khan, U., Phillips, P. P. J., Velásquez, G. E., Furin, J., Spigelman, M., Denholm, J. T., Thi, S. S., Tiberi, S., Huang, G. K. L., Marks, G. B., Turkova, A., Guglielmetti, L., Chew, K. L., Nguyen, H. T., Ong, C. W. M., Brigden, G., Singh, K. P., Motta, I., Lange, C., Seddon, J. A., Nyang'wa, B-T., Maug, A. K. J., Gler, M. T., Dooley, K. E., Quelapio, M., Tsogt, B., Menzies, D., Cox, V., Upton, C. M., Skrahina, A., McKenna, L., Horsburgh, C. R., Dheda, K., Marais, B. J.

“…BACKGROUND: The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best…”
Get full text

Palliative care and symptom relief for people affected by multidrug-resistant tuberculosis by Krakauer, E. L., Dheda, K., Kalsdorf, B., Kuksa, L., Nadkarni, A., Nhung, N. V., Selwyn, P., Shin, S., Skrahina, A., Jaramillo, E.

“…The World Health Organization (WHO) defines palliative care as the prevention and relief of the physical, psychological, social and spiritual suffering of…”
Get full text

A new health care index predicts short term mortality for TB and HIV co-infected people by Roen, A. O., Podlekareva, D., Miller, R. F., Mocroft, A., Panteleev, A., Skrahina, A., Miro, J. M., Cayla, J. A., Tetradov, S., Derisova, E., Furrer, H., Losso, M. H., Vassilenko, A., Girardi, E., Lundgren, J. D., Post, F. A., Kirk, O.

“…BACKGROUND: Using 2004-2007 TB:HIV Study data from Europe and Latin America, we previously generated a health care index (HCI) for TB and HIV co-infected…”
Get full text

Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond by D’Ambrosio, L, Bothamley, G, Caminero Luna, J.A, Duarte, R, Guglielmetti, L, Muñoz Torrico, M, Payen, M.C, Saavedra Herrera, N, Salazar Lezama, M.A, Skrahina, A, Tadolini, M, Tiberi, S, Veziris, N, Migliori, G.B

“…AbstractAs recommended by the World Health Organization (WHO), optimal management of MDR-TB cases can be ensured by a multi-speciality consultation body known…”
Get full text

Sputum smear microscopy result: a predictor for drug-resistant tuberculosis? by Dean, A. S., Zignol, M., Lumb, R., Lalor, M., Skrahina, A., Floyd, K.

“…Until countries establish capacity for continuous surveillance systems, representative surveys of tuberculosis (TB) patients continue to improve our…”
Get full text

One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America by Podlekareva, D.N., Schultze, A., Panteleev, A., Skrahina, A.M., Miro, J.M., Rakhmanova, A., Furrer, H., Miller, R.F, Efsen, A.M.W., Losso, M.H., Toibaro, J., Vassilenko, A., Girardi, E., Lundgren, J.D., Mocroft, A., Post, F.A., Kirk, O.

“…OBJECTIVES:The high mortality among HIV/tuberculosis (TB) coinfected patients in Eastern Europe is partly explained by the high prevalence of drug-resistant…”
Get full text

Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe by Mansfeld, M, Skrahina, A, Shepherd, L, Schultze, A, Panteleev, AM, Miller, RF, Miro, JM, Zeltina, I, Tetradov, S, Furrer, H, Kirk, O, Grzeszczuk, A, Bolokadze, N, Matteelli, A, Post, FA, Lundgren, JD, Mocroft, A, Efsen, AMW, Podlekareva, DN

“…Objectives The aim of the study was to investigate the organization and delivery of HIV and tuberculosis (TB) health care and to analyse potential differences…”
Get full text